Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company developing masked immuno-oncology therapies designed to activate within tumors, where tumor-specific proteases release the masks and enable localized activity. Its pipeline includes XTX501, a bispecific PD-1 and masked IL-2 candidate;… From the company’s description.
Over the twelve months to Jun 30, 2026, Xilio Therapeutics, Inc. reported revenue of $64.09M, up 327.3% from a year earlier, and a net loss of $21.83M. Its operating margin was −48.9%, and operations used $60.60M in cash. In fiscal 2025, it reported revenue of $43.77M, up 589.9% from fiscal 2024, and a net loss of $35.04M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Xilio Therapeutics, Inc. does
In the company’s own words
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company developing masked immuno-oncology therapies designed to activate within tumors, where tumor-specific proteases release the masks and enable localized activity. Its pipeline includes XTX501, a bispecific PD-1 and masked IL-2 candidate; masked T cell engagers targeting PSMA and STEAP1 or CLDN18.2; efarindodekin alfa, a masked IL-12 being evaluated in a Phase 2 trial; and vilastobart, a masked anti-CTLA-4 antibody. The company’s programs are in preclinical and clinical development, and it collaborates with AbbVie on masked immunotherapies and has licensed Gilead an option related to efarindodekin alfa and its IL-12 program. Xilio also has a co-funded clinical trial collaboration with Roche to evaluate vilastobart with atezolizumab. Its proprietary platform uses protein engineering and tumor-specific protease-cleavable masking to design biologics, including antibody and T cell engager formats. The company reports one business, with no separate reportable segments identified in the provided business description. Its website is www.xiliotx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1840233
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Xilio Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Xilio Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Xilio Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Xilio Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Xilio Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”